Quantum BioPharma Ltd. (QNTM)

NCM – Real Time Price. Currency in USD

3.80

-0.13 (-3.31%)

At close: Jun 26, 2026, 4:00 PM EDT

3.81

+0.01 (0.23%)

After-hours: Jun 26, 2026, 7:38 PM EDT

02.06.2026

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Disseminated on behalf of Quantum BioPharma , may include paid advertisements. AUSTIN, Texas, June 02, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

02.06.2026

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, is pleased to announce that it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC (the “Agency”) beginning on June 8, 2026.

01.06.2026

Quantum BioPharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

18.05.2026

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results.

07.05.2026

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its financial and operational results for the first quarter of 2026, ended March 31, 2026.

27.04.2026

Quantum BioPharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

22.04.2026

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the “Company”), the company behind unbuzzd™, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, is pleased to announce the appointment of Mr. Richard Buzbuzian as Chief Executive Officer. This marks a pivotal milestone in the Company's commercialization strategy. With the functional beverage market projected to reach $198 billion in 2026 and expected to grow at a 10.79% CAGR, Mr. Buzbuzian brings the vision and capital markets acumen required to capitalize on this unprecedented market opportunity. His mandate includes executing a nationwide rollout beginning with strategic market expansion into South Florida and Texas — two of America's most dynamic consumer markets, as well as listing the Company on a stock exchange.

Videos

No Data

There is no data to display

Press releases

02.06.2026

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

02.06.2026

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

01.06.2026

Quantum BioPharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

18.05.2026

Quantum BioPharma Ltd. (QNTM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Quantum BioPharma Ltd. (QNTM)

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

Videos

No Data

Press releases

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

Videos

No Data

Press releases

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Search stocks

Quantum BioPharma Ltd. (QNTM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Quantum BioPharma Ltd. (QNTM)

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

Videos

No Data

Press releases

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

Videos

No Data

Press releases

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital